TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07639450: A Phase I/II Clinical Study Evaluating the Safety, Tolerability, and Efficacy of N-3C01 as Monotherapy and in Combination With PD-(L)1 Monoclonal Antibody in Patients With Advanced Malignant Solid Tumors

Sponsor: Hefei Xinzhu Biological Technology Co., Ltd. · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 114 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$11,191,950

Rescue Site Savings

+$7,382,760

Unlock Full NCT07639450 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07639450 Rescue Dossier →